Opus’s New Gene Therapy Clinical Trial Knocks on the Healthcare Door

Introduction

Opus Genetics, a clinical-inspired biopharmaceutical company known for its one-time adeno-associated virus (AAV)-related gene therapies, sincerely developed them for inherited retinal diseases (IRDs). This company came into the healthcare frame because of the Foundation Fighting Blindness’s RD Fund. The company conducts programs to treat particular genetic damage of vision loss.

The programs like BEST1 and LCA5 are the popular programs to date. The impeccable pipeline of the company flaunts seven AAV-related gene therapy candidates for RHO, MERTK, RDH12, etc. The company’s leadership quality and partnership journey are the talk of the healthcare town, due to its origin and success throughout the company’s life cycle.

Announcement

Opus Genetics, Inc., took this golden moment to announce its funding and inauguration of a new clinical trial at Abu Dhabi in partnership with the Authority of Social Contribution (Ma’an), the Department of Health, Abu Dhabi (DoH), Cleveland Clinic Abu Dhabi, and the Innovative Research Oversight and Support (IROS) branch of the M42 group.

What will this new clinical trial do?

This new clinical trial will assess a gene therapy for progressive MERTK-based retinitis pigmentosa (RP). It’s a rare inherited eye condition that leads to an unfortunate scenario of blindness and vision loss. It will also capture the efficacy and safety volume of OPGx-MERTK, Opus’s AAV-related gene therapy. The therapy is brought into vision to serve functional hint of the MERTK gene to retinal cells.

MERTK silence disconnects retinal potency volume of recycling/reviving photoreceptor components, causes degeneration, and eliminates vision. As of now, there are no such qualified treatments for MERTK-based retinitis pigmentosa. This clinical trial is a hope for the patients to see a beautiful tomorrow in life with the help of apt therapy for the same.

This year, Abu Dhabi will witness this robust clinical development operations which is a success for precision medicine and rare disease findings. This will benefit the global population as well as the healthcare enthusiasts to perform, invest or collaborate in this kind of clinical development.

M.D., Chief Executive Officer of Opus Genetics, George Magrath expressed its excitement and took the honour to appreciate its partners and this recent partnership with DoH, Abu Dhabi. Whereas, Undersecretary of the DoH-Abu Dhabi, H.E. Dr Noura AL Ghaithi, also showed its equal excitement for hosting the first-ever MERTK gene therapy clinical trial at its own land, the United Arab Emirates (UAE), Abu Dhabi.